What's Happening?
AstraZeneca and Ionis have encountered a significant setback with the late-stage failure of their antisense oligonucleotide, Wainua, in treating transthyretin amyloidosis cardiomyopathy (ATTR-CM). This unexpected outcome has cast doubt on similar therapies,
while simultaneously boosting investor confidence in other companies within the field. Wainua was designed to suppress the expression of the transthyretin (TTR) protein, which misfolds in ATTR-CM, leading to harmful clumps in the heart. The failure of Wainua has left Alnylam's FDA-approved Amvuttra as the only approved TTR silencer for ATTR-CM, although it raises questions about the future of Alnylam's next-generation candidate, nucresiran. Meanwhile, BridgeBio and Intellia Therapeutics are seeing positive impacts, with BridgeBio's TTR stabilizer, Attruby, gaining attention for its potential renal benefits and survival edge over competitors.
Why It's Important?
The failure of Wainua is pivotal as it reshapes the competitive landscape for ATTR-CM treatments. Alnylam's position is both strengthened and challenged, as it remains the sole provider of an approved TTR silencer but faces uncertainty with its upcoming candidate, nucresiran. The setback for AstraZeneca and Ionis simplifies the market, potentially increasing the market share for BridgeBio's Attruby, which has shown promising results in preserving kidney function and improving survival rates. This development could lead to increased sales and a stronger market position for BridgeBio. Additionally, Intellia Therapeutics' CRISPR-based gene therapy, nexiguran ziclumeran, may benefit from the reduced competition, as it offers a one-time treatment option that could appeal to patients and healthcare providers seeking effective long-term solutions.
What's Next?
Alnylam is continuing its Phase 3 TRITON-CM study for nucresiran, with results expected by 2030. The company remains confident in its candidate, citing its potency, durability, and the experience of its leadership team. BridgeBio is likely to capitalize on the current market dynamics to enhance the positioning of Attruby, potentially increasing its sales projections. Intellia Therapeutics, having overcome an FDA hold on its trials, will proceed with its studies, aiming to establish its gene therapy as a viable alternative in the ATTR-CM treatment space. The industry will closely monitor these developments, as the outcomes could significantly influence treatment options and market dynamics in the coming years.
